Description：Enzyme Immunoassay for quantitative detection of Tremelimumab in serum and plasma.
Tremelimumab （formerly ticilimumab, CP-675,206） is a fully human monoclonal antibody against CTLA-4.
It is an immune checkpoint blocker.
Cytotoxic T lymphocytes （CTLs） can recognize and destroy cancer cells.
However, there is also an inhibitory mechanism （immune checkpoint） that interrupts this destruction.
Tremelimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy the cancer cells.
Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well.
About the kit：
- Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115％
- Ready to use with a standard protocol with break-apart pre-coated wells
- Validated as per US FDA guidelines for Bioassays
- Optimized for matrix effects to ensure higher sensitivity.
- Shelf life： 1 year
The method employs the quantitative enzyme immunoassay technique.
Standards or samples are pipetted into microwells pre-coated with Anti- Tremelimumab antibody and Tremelimumab present in the sample and standards are bound by Anti- Tremelimumab antibody.
In the second step, Detection antidody is added and incubated.
In the third step, a HRP conjugate is pipetted and incubated.
Free HRP conjugate will be removed by washing.
Addition of TMB substrate will develop blue color and intensity of blue colour in wells is proportional to the concentration of Tremelimumab present in standard or sample.
Color development is then stopped by addition of stop solution.
